Biolojic Design is pioneering a transformative approach to antibody development by leveraging machine learning to create programmable antibodies that function as dynamic switches within biological systems. Their platform enables the design of antibodies that can precisely bind to predefined epitopes, allowing for targeted modulation of biological pathways. This innovative technology aims to enhance drug efficacy while minimizing toxicity, as the antibodies can respond to specific micro-environments in the body, adjusting their activity based on the patient's unique condition. By focusing on well-established biological pathways, Biolojic's AI-designed antibodies are positioned to address complex diseases, particularly in the realms of autoimmune disorders and immuno-oncology.

The company's therapeutic pipeline includes several groundbreaking candidates, such as AU-007, the first computationally designed antibody to enter human clinical trials, which selectively redirects interleukin-2 to enhance anti-tumor responses. Additionally, Biolojic is developing multibodies, which are capable of targeting multiple antigens simultaneously, thereby improving treatment outcomes for inflammatory diseases. Their approach not only aims to increase the therapeutic index of existing treatments but also seeks to personalize therapy by dynamically adjusting to the patient's needs. Through these advanced technologies, Biolojic Design is committed to redefining the landscape of drug development and improving patient outcomes in challenging therapeutic areas.

Israel

Biolojic Design makes developable, active human antibodies directed against functional epitopes, including targets for which existing technologies fail.

Biolojic Design

Company Details